Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.

BMC gastroenterology·2021

Same author

Downregulation of circFASTKD1 ameliorates myocardial infarction by promoting angiogenesis.

Aging·2021

Same author

A Special Report on 2019 International Planning Competition and a Comprehensive Analysis of Its Results.

Frontiers in oncology·2020

Same author

Tomato protein phosphatase 2C influences the onset of fruit ripening and fruit glossiness.

Journal of experimental botany·2020

Same author

CT changes of severe coronavirus disease 2019 based on prognosis.

Scientific reports·2020

Same author

Meta-neural-network for real-time and passive deep-learning-based object recognition.

Nature communications·2020

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Donor-derived solid malignancies after hematopoietic stem cell transplantation.

Yong-xian Hu¹, Qu Cui, Bin Liang

¹Center of Hematology and Bone Marrow Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, 310003 Hangzhou, Zhejiang, China.

|April 15, 2010

Summary

This summary is machine-generated.

Allogeneic stem cell transplants offer benefits but carry risks. This review examines donor-derived solid tumors after transplantation, exploring causes and future prevention strategies.

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Jun 13, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

Hematology
Oncology
Transplantation Medicine

Background:

Allogeneic hematopoietic stem cell transplantation (HSCT) is a vital treatment for hematologic diseases.
Long-term survivors highlight HSCT's efficacy but face risks like secondary solid malignancies.
Secondary malignancies can arise from recipients, donors, or unknown origins.

Purpose of the Study:

To review current clinical evidence on donor-derived solid malignancies post-HSCT.
To explore potential mechanisms underlying these malignancies.
To discuss new indications, therapies, and prevention strategies.

Main Methods:

Literature review of clinical studies and case reports.
Analysis of reported cases of donor-derived malignancies.
Synthesis of proposed etiological mechanisms and therapeutic approaches.

Main Results:

Evidence indicates that solid tumors can be transmitted from donors to recipients post-HSCT.
Potential mechanisms include oncogenic virus transmission and donor cell-mediated oncogenesis.
The incidence and specific types of donor-derived malignancies are still being fully elucidated.

Conclusions:

Donor-derived solid malignancies represent a significant late complication of HSCT.
Further research into donor screening, risk stratification, and targeted therapies is crucial.
Proactive monitoring and preventive strategies are needed to improve long-term outcomes for HSCT recipients.